Myriad Genetics News

Myriad Pharmaceuticals today announced the company has entered into a definitive agreement to acquire Javelin Pharmaceuticals .

Myriad Genetics, Inc. announced today that Peter D. Meldrum, President and CEO, is scheduled to present an overview of the Company at the 28th Annual J.P. Morgan Healthcare Conference, at 10:30 a.m. Pacific on January 13, 2010, at the Westin St.

December 11, 2009 - Next up, there are two gene mutations that drastically increase the risk of breast and ovarian cancer in women who have them.

At age 36, after a diagnosis of breast cancer, Genae Girard had a double mastectomy.

Swiss privacy watchdog to sue Google Street View 11/13/2009 3:47am Switzerland's privacy watchdog is taking legal action to force Google to make changes to its Street View service.

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the... CHICAGO-- --Zacks Equity Research highlights Infosys as the Bull of the Day and Myriad Genetics Inc.

Medicis Pharmaceutical Corp. posted a third-quarter profit on Wednesday, as sales of its skin products surged, and a research and development charge came off the books.

Myriad Pharmaceuticals Inc. on Friday reported a smaller fiscal first-quarter loss on lower research costs after the company was spun off from Myriad Genetics Inc.

Myriad Pharmaceuticals, Inc. today reported financial results for its first fiscal quarter ended September 30, 2009.

Myriad Pharmaceuticals Inc. on Friday reported a smaller fiscal first-quarter loss on lower research costs after the company was spun off from Myriad Genetics Inc.

Myriad Pharmaceuticals Inc. filed Quarterly Report for the period ended 2009-09-30. Myriad Pharmaceuticals, Inc.

The case revolves around seven patents relating to human genes BRCA1 and BRCA2, mutations of which have been tied to breast and ovarian cancer.

In May, the ACLU announced that it was suing to invalidate a patent that covers testing for genetic variants associated with breast cancer.

A federal district judge ruled yesterday that a lawsuit challenging patents on genes related to hereditary breast and ovarian cancer can move forward in court.

A federal judge ruled Monday that a lawsuit can move forward against the Patent and Trademark Office and the research company that was awarded exclusive rights to human genes known to detect early signs of breast and ovarian cancer.

The recommendations were supported by a variety of health professionals but put the biotechnology industry on edge.

Myriad Genetics, Inc. today announced it has obtained from Johns Hopkins University a world-wide, exclusive license to patents covering mutations in the PALB2 gene that increase an individual's risk for developing pancreatic cancer later in life.

Myriad Pharmaceuticals, Inc. today announced the identification of an Investigational New Drug candidate targeting a novel molecular target, the protein kinase IKK epsilon.

Myriad Genetics, Inc. today announced that it will release its fiscal 2010 first quarter financial results at the close of market on Tuesday, November 3, 2009.

Seats are filling fast for The Utah Technology Council's 11th annual Hall of Fame black-tie gala with Eric Schmidt, Chairman of the Board and CEO of Google Inc., as the keynote speaker.